Transthyretin cardiac amyloidoses in older North Americans

Journal of the American Geriatrics Society

Volumn 60, Issue 4, 2012, Pages 765-774

  Dharmarajan, Kumar ^a   Maurer, Mathew S ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

Aging; Amyloidosis; Cardiomyopathy; Heart failure; Transthyretin

Indexed keywords

AMIODARONE; AMYLOID; ANGIOTENSIN RECEPTOR ANTAGONIST; APIXABAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUMETANIDE; CALCIUM CHANNEL BLOCKING AGENT; DABIGATRAN; DIFLUNISAL; DIGOXIN; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUDROCORTISONE; FUROSEMIDE; MIDODRINE; NONSTEROID ANTIINFLAMMATORY AGENT; PREALBUMIN; PSEUDOEPHEDRINE; SMALL INTERFERING RNA; TAFAMIDIS; THIAZIDE DIURETIC AGENT; TORASEMIDE; WARFARIN;

AGED; ALZHEIMER DISEASE; AMINO ACID SUBSTITUTION; AMYLOIDOSIS; ARRHYTHMOGENESIS; ARTIFICIAL HEART PACEMAKER; ATRIOVENTRICULAR BLOCK; BONE MARROW TRANSPLANTATION; CARDIAC IMAGING; CARDIAC TRANSTHYRETIN AMYLOIDOSIS; CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; CASE REPORT; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; ELECTROCARDIOGRAPHY MONITORING; FAMILIAL AMYLOIDOTIC CARDIOMYOPATHY; FLUID RETENTION; GASTRITIS; GENE MUTATION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART MUSCLE BIOPSY; HEART MUSCLE CONDUCTION DISTURBANCE; HEART PROARRHYTHMIA; HEART TRANSPLANTATION; HUMAN; HYPOTENSION; KIDNEY DISEASE; MALE; MUTATIONAL ANALYSIS; PARKINSON DISEASE; PATHOGENESIS; PEPTIC ULCER; POLYNEUROPATHY; PROGNOSIS; PROTEIN FOLDING; RESTRICTIVE CARDIOMYOPATHY; REVIEW; RNA INTERFERENCE; SIDE EFFECT; THROMBOSIS; TRANSTHORACIC ECHOCARDIOGRAPHY; UNITED STATES; WILD TYPE;

AFRICAN AMERICANS; AGED; AGING; AMYLOIDOSIS; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MUTATION; MYOCARDIUM; NEW YORK; PREALBUMIN;

EID: 84859853882     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2011.03868.x     Document Type: Review

References (60)

1. Shah KB, Inoue Y, Mehra MR. Amyloidosis and the heart: A comprehensive review. Arch Intern Med 2006;166:1805-1813. (Pubitemid 44455160)
2. Desai HV, Aronow WS, Peterson SJ et al. Cardiac amyloidosis: Approaches to diagnosis and management. Cardiol Rev 2010;18:1-11.
3. Rapezzi C, Quarta CC, Riva L et al. Transthyretin-related amyloidoses and the heart: A clinical overview. Nat Rev Cardiol 2010;7:398-408.
4. Westermark P, Benson MD, Buxbaum JN et al. Amyloid: Toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 2005;12:1-4.
5. Falk RH, Dubrey SW. Amyloid heart disease. Prog Cardiovasc Dis 2010;52:347-361.
6. Buxbaum J, Alexander A, Koziol J et al. Significance of the amyloidogenic transthyretin Val 122 Ile allele in African-Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies. Am Heart J 2010;159:864-870.
7. Jacobson D, Tagoe C, Schwartzbard A et al. Relation of clinical, echocardiographic and electrocardiographic features of cardiac amyloidosis to the presence of the transthyretin V122I allele in older African-American men. Am J Cardiol 2011;108:440-444.
8. Cohen FE, Kelly JW. Therapeutic approaches to protein-misfolding diseases. Nature 2003;426:905-909. (Pubitemid 38056884)
9. Dobson CM. Protein folding and misfolding. Nature 2003;426:884-890. (Pubitemid 38056880)
10. Dohm CP, Kermer P, Bahr M. Aggregopathy in neurodegenerative diseases: Mechanisms and therapeutic implication. Neurodegener Dis 2008;5:321-338.
11. Brenner DA, Jain M, Pimentel DR et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 2004;94:1008-1010. (Pubitemid 38579694)
12. Shi J, Guan J, Jiang B et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci U S A 2010;107:4188-4193.
13. Walsh DM, Klyubin I, Fadeeva JV et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002;416:535-539. (Pubitemid 34288854)
14. Cohen E, Bieschke J, Perciavalle RM et al. Opposing activities protect against age-onset proteotoxicity. Science 2006;313:1604-1610. (Pubitemid 44414028)
15. Macario AJ, Conway de Macario E. Sick chaperones and ageing: A perspective. Ageing Res Rev 2002;1:295-311. (Pubitemid 38340347)
16. Jacobson DR, Pastore R, Pool S et al. Revised transthyretin Ile 122 allele frequency in African-Americans. Hum Genet 1996;98:236-238. (Pubitemid 26237513)
17. Jacobson DR, Pastore RD, Yaghoubian R et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 1997;336:466-473. (Pubitemid 27074357)
18. Sekijima Y, Yoshida K, Tokuda T et al. Familial transthyretin amyloidosis. In: Pagon RA, Bird TD, Dolan CR, Stephens K eds. GeneReviews - NCBI Bookshelf (Internet). Seattle: University of Washington, Seattle. 1993 present [on-line]. Available at http://www.ncbi.nlm.nih.gov/books/NBK1194/#tfap. Molecular-Genetics Accessed June 12, 2011.
19. Dharmarajan K, Salomon S, Helmke S et al. Genotype and phenotypic characteristics of persons with cardiac amyloidosis from the multinational Transthyretin Amyloidosis Outcomes Survey (THAOS) registry. J Cardiac Fail 2011;17:S69.
20. Bhuiyan T, Helmke S, Patel AR et al. Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin: Transthyretin Cardiac Amyloid Study (TRACS). Circ Heart Fail 2011;4:121-128.
21. Ng B, Connors LH, Davidoff R et al. Senile systemic amyloidosis presenting with heart failure: A comparison with light chain-associated amyloidosis. Arch Intern Med 2005;165:1425-1429. (Pubitemid 40973426)
22. Rapezzi C, Merlini G, Quarta CC et al. Systemic cardiac amyloidoses: Disease profiles and clinical courses of the 3 main types. Circulation 2009;120:1203-1212.
23. Tanskanen M, Peuralinna T, Polvikoski T et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: A population-based autopsy study. Ann Med 2008;40:232-239. (Pubitemid 351482541)
24. Sultan AM, Edwards WD, Mohammed SF et al. Cardiac amyloid deposition is common in elderly patients with heart failure and preserved ejection fraction. Circulation 2010;122:A17926.
25. Bergstrom J, Gustavsson A, Hellman U et al. Amyloid deposits in transthyretin-derived amyloidosis: Cleaved transthyretin is associated with distinct amyloid morphology. J Pathol 2005;206:224-232. (Pubitemid 40754027)
26. Greene MJ, Sam F, Soo Hoo PT et al. Evidence for a functional role of the molecular chaperone clusterin in amyloidotic cardiomyopathy. Am J Pathol 2011;178:61-68.
27. Goncalves I, Alves CH, Quintela T et al. Transthyretin is up-regulated by sex hormones in mice liver. Mol Cell Biochem 2008;317:137-142.
28. Feng D, Syed IS, Martinez M et al. Intracardiac thrombus and anticoagulation therapy in cardiac amyloidosis. Circulation 2009;119:2490-2497.
29. Falk RH, Rubinow A, Cohen AS. Cardiac arrhythmias in systemic amyloidosis: Correlation with echocardiographic abnormalities. J Am Coll Cardiol 1984;3:107-113. (Pubitemid 14219960)
30. Connors LH, Prokaeva T, Lim A et al. Cardiac amyloidosis in African Americans: Comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J 2009;158:607-614.
31. Noumi B, Latif F, Helmke S et al. Differences between transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild type TTR presenting to a tertiary referral center. J Card Fail 2010;16:S40.
32. Kyle RA, Spittell PC, Gertz MA et al. The premortem recognition of systemic senile amyloidosis with cardiac involvement. Am J Med 1996;171:395-400. (Pubitemid 26392857)
33. Latif F, Delisle S, Helmke S et al. Changes in the type of cardiac amyloidosis diagnosed at a tertiary referral center: An impact of an aging population. J Am Coll Cardiol 2011;57:E247.
34. Austin BA, Duffy B, Tan C et al. Comparison of functional status, electrocardiographic, and echocardiographic parameters to mortality in endomyocardial-biopsy proven cardiac amyloidosis. Am J Cardiol 2009;103:1429-1433.
35. Selvanayagam JB, Hawkins PN, Paul B et al. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol 2007;50:2101-2110. (Pubitemid 350117349)
36. Rahman JE, Helou EF, Gelzer-Bell R et al. Non-invasive diagnosis of biopsy proven cardiac amyloidosis. J Am Coll Cardiol 2004;43:410-415. (Pubitemid 38167701)
37. Hosch W, Kristen AV, Libicher M et al. Late enhancement in cardiac amyloidosis: Correlation of MRI enhancement pattern with histopathological findings. Amyloid 2008;15:196-204.
38. Sun JP, Stewart WJ, Yang XS et al. Differentiation of hypertrophic cardiomyopathy and cardiac amyloidosis from other causes of ventricular wall thickening by two-dimensional strain imaging echocardiography. Am J Cardiol 2009;103:411-415.
39. Maceira AM, Joshi J, Prasad SK et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005;111:186-193. (Pubitemid 40139730)
40. Syed IS, Glockner JF, Feng D et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging 2010;3:155-164.
41. Austin BA, Tang WHT, Rodriguez ER et al. Delayed hyperenhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovasc Imaging 2009;2:1369-1377.
42. Perugini E, Guidalotti PL, Salvi F et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-Diphosphono-1,2-Propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005;46:1076-1084. (Pubitemid 41316518)
43. 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging 2011;38:470-478.
44. Rapezzi C, Quarta CC, Guidalotti PL et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging 2011;4:659-670.
45. Ardehali H, Qasim A, Cappola T et al. Endomyocardial biopsy plays a role in diagnosing patients with unexplained cardiomyopathy. Am Heart J 2004;147:919-923. (Pubitemid 38881009)
46. Wargo KA, Banta WM. A comprehensive review of the loop diuretics: Should furosemide be first line? Ann Pharmacother 2009;43:1836-1847.
47. Nihoyannopoulos P, Dawson D. Restrictive cardiomyopathies. Eur J Echocardiogr 2009;10:iii23-iii33.
48. Holzmeister J, Leclercq C. Implantable cardioverter defibrillators and cardiac resynchronization therapy. Lancet 2011;378:722-730.
49. Low PA, Gilden JL, Freeman R et al. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA 1997;277:1046-1051.
50. United States Food and Drug Administration. FDA news release: FDA proposes withdrawal of low blood pressure drug [on-line]. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm222580.htm Accessed November 16, 2011.
51. Rubinow A, Skinner M, Cohen AS. Digoxin sensitivity in amyloid cardiomyopathy. Circulation 1981;63:1285-1288. (Pubitemid 11120664)
52. Gertz MA, Falk RH, Skinner M et al. Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. Am J Cardiol 1985;55:1645. (Pubitemid 15059308)
53. Kang GH, Dong RR, Song PS et al. A case of a senile systemic amyloidosis patient presenting with angina pectoris and dilated cardiomyopathy. Korean Circ J 2011;41:209-212.
54. Maurer MS, Raina A, Hesdorffer C et al. Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure. Transplantation 2007;83:539-545. (Pubitemid 46440239)
55. Bartolini M, Andrisano V. Strategies for the inhibition of protein aggregation in human diseases. Chembiochem 2010;11:1018-1035.
56. Sekijima Y, Dendle MA, Kelly JW. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid 2006;13:236-249. (Pubitemid 44764463)
57. Coelho T, Maia M, Martins da Silva A et al. Tafamidis (Fx-1006A): A first-in-class disease-modifying therapy for transthyretin type familial amyloid polyneuropathy. Abstract presented at American Academy of Neurology annual meeting, 2010.
58. Falk RH, Maurer MS, Fedson SE et al. Tafamidis stabilizes transthyretin and improves clinical outcomes in transthyretin amyloid cardiomyopathy. J Cardiac Fail 2011;17:S56.
59. Zimmermann TS, Lee AC, Akinc A et al. RNAi-mediated gene silencing in non-human primates. Nature 2006;441:111-114.
60. Benson MD, Kluve-Beckerman B, Zeldenrust SR et al. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve 2006;33:609-618.